GLP-1 receptor agonists could hold promise for opioid use disorder treatment
Treatment for OUD is currently dominated by opioid agonist therapies that are highly regulated due to their liability for ...
infectiousdiseaseadvisor.com1d
Many With Overweight, Obesity Discontinue GLP-1 Receptor Agonists Within 1 Year
Many patients with overweight or obesity discontinue GLP-1 receptor agonist therapy within 1 year, with higher discontinuation rates seen for those without type 2 diabetes.
Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast 2023-2033
Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast" report has been added to ResearchAndMarkets.com's offering.Across the 68 markets, sales ...
Daily4d
SGLT2 Inhibitors and GLP-1 Receptor Agonists Linked to Fewer COPD Exacerbations in diabetes patients with COPD: JAMA
Researchers had found in a new study that sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 ...